Meropenem-valproic acid interaction in patients with cefepime-associated status epilepticus

American Journal of Health-System Pharmacy

Volumn 64, Issue 1, 2007, Pages 54-58

  Spriet, Isabel ^a   Meersseman, Wouter ^a   De Troy, Elke ^b   Wilmer, Alexander ^c   Casteels, Minne ^d   Willems, Ludo ^e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b VIRGA JESSE HOSPITAL   (Belgium)

^c Medical Intensive Care Unit   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UHL   (Belgium)

Author keywords

Antibiotics; Anticonvulsants; Blood levels; Cefepime; Cephalosporins; Drug interactions; Meropenem; Status epilepticus; Toxicity; Valproic acid

Indexed keywords

CASPOFUNGIN; CEFEPIME; CEFTAZIDIME; ETIRACETAM; IMIPENEM; MEROPENEM; PHENOBARBITAL; PHENYTOIN; PIPERACILLIN PLUS TAZOBACTAM; REMIFENTANIL; VALPROIC ACID; VANCOMYCIN; VORICONAZOLE;

ADD ON THERAPY; ADULT; ARTICLE; BACTEREMIA; CASE REPORT; CAUSE OF DEATH; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPILEPSY; EPILEPTIC STATE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INTENSIVE CARE UNIT; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; MALE; MYELODYSPLASIA; PNEUMONIA; PRIORITY JOURNAL; SEIZURE;

EID: 33947130134     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050512     Document Type: Article

References (29)

1. Preskorn SH. How drug-drug interactions can impact managed care. Am J Manag Care. 2004; 10:5186-98.
2. Plensa E, Gallardo E, Ribera JM et al. Nonconvulsive status epilepticus associated with cefepime in a patient undergoing autologous stem cell transplantation. Bone Marrow Transpl. 2004; 33:119-20.
3. Rimmer EM, Richens A. An update on sodium valproate. Pharmacotherapy. 1985; 5:171-84.
4. Zaccara G. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet. 1988; 15:367-89.
5. Bruni J, Wilder BJ, Willmore LJ et al. Steady-state kinetics of valproic acid in epileptic patients. Clin Pharmacol Ther. 1978; 24:693-720.
6. Vree TB, Van Der Kleijn E. Pharmacokinetics and renal excretion of 2-n-propylpentanoate (Depakine) in man, dog and rhesus monkey. Pharm Weekbl. 1977; 112:290-2.
7. Dickinson RG, Harland RC, Robert DH et al. Disposition of valproic acid in the rat: dose-dependent metabolism, distribution, enterohepatic recirculation and choleretic effect. J Pharmacol Exp Ther. 1979; 211:583-95.
8. Mouton JW, Van Den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet. 1995; 28:275-89.
9. Bax RP, Bastain W, Featherstone A et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chem. 1989; 24:311-20.
10. Norrby SR. Neurotoxicity of carbapenem antibacterials. Drug Saf. 1996; 15:87-90.
11. Stockley IH. General considerations and an outline survey of some basic interaction mechanisms. In: Stockley IH, ed. Drug interactions: a source book of adverse interactions, their mechanisms, clinical importance and management. 3rd ed. Oxford, England: Blackwell Scientific; 1994:6-9.
12. Pisani F. Influence of co-medication on the metabolism of valproate. Pharm Weekbl Sci. 1992; 14:108-13.
13. Keller F, Maiga M, Neumayer HH et al. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. Eur J Drug Metab Pharmacokinet. 1984; 9:275-82.
14. Urien S, Albengres E, Tillement JP. Serum protein binding of valproic acid in healthy subjects and in patients with liver disease. Int J Clin Pharmacol Ther Toxicol. 1981; 19:319-25.
15. Grondahl TO, Langmoen IA. Epileptogenic effect of antibiotic drugs. J Neurosurg. 1993; 78:938-43.
16. Nagai K, Shimizu T, Togo A et al. Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron. J Antimcrob Chemother. 1997; 39:295-6.
17. De Turck BJ, Diltoer MW, Cornelis PJ et al. Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin. J Antimicrob Chemother. 1998; 42:563-4.
18. Yamagata T, Momoi MY, Murai K et al. Panipenem-betamipron and decreases in serum valproic acid concentration. Ther Drug Monit. 1998; 20:396-400.
19. Nacarkucuk E, Saglam H, Okan M. Meropenem decreases serum level of valproic acid. Pediatr Neurol. 2004; 31: 232-4.
20. Coves-Orts FJ, Borras-Blasco J, Navarro-Ruiz A et al. Acute seizures due to a probable interaction between valproic acid and meropenem. Ann Pharmacother. 2005; 39:533-7.
21. Santucci M, Parmeggiani A, Riva R. Seizure worsening caused by decreased serum valproate during meropenem therapy. J Child Neurol. 2005; 20:456-7.
22. Lam F. Valproic acid taken with meropenem may result in seizures. Brown Univ Psychopharmacol Update. 2005. 16:2-3.
23. Clause D, Decleire PY, Vanbinst R et al. Pharmacokinetic interaction between valproic acid and meropenem. Intens Care Med. 2005; 31:1293-4.
24. Kojima S, Nadai M, Kitaichi K et al. Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats. Antimicrob Agents Chemother. 1998; 42:3136-40.
25. Yamamura N, Imura K, Naganuma H et al. Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats. Drug Metab Dispos. 1999; 6:724-30.
26. Nakajima Y, Mizobuchi M, Nakamura M et al. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos. 2004; 32:1383-91.
27. Hobara N, Hokama N, Ohshiro S et al. Possible mechanisms of low levels of plasma valproate concentration following simultaneous administration of sodium valproate and meropenem. Biogenic Amines. 2003; 17:409-20.
28. Dickinson RG, Taylor SM, Kaufman SN. Nonlinear elimination and choleretic effect of valproic acid in the monkey. J Pharmacol Exp Ther. 1980; 213:38-48.
29. Yamamura N, Imura-Miyoshi K, Naganuma H. Panipenem, a carbapenem antibiotic, increases the level of hepatic UDP-glucuronic acid in rats. Drug Metab Dispos. 2000; 28:1484-6.